PATENT CLAIM ANALYSIS

Application Number: 16164883
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-02
Patent Classification: ["424", "135100"]

Abstract:
The present invention relates to methods of treating patients suffering from itching and puritis mediated by cutaneous lymphocyte antigen positive T cell. In particular, diseases or disorders including contact dermatitis, drug induced delayed type cutaneous allergic reactions, toxic epidermal necrolysis, cutaneous T cell lymphoma, bullous pemphigoid, alopecia aereata, vitiligo, acne rosacea, prurigo nodularis, and herpes simplex virus, or combination thereof will benefit from the administration of an IL-31 antagonist. The invention also includes methods of predicting a therapeutically responsive patient population.

Claim (Index 6):
The method of  claim 4 , wherein the antibody fragment is selected from the group consisting of:\n a) a Fab fragment; b) a Fab\u2032 fragment; c) a Fv fragments; d) a F(ab\u2032) 2  fragment; and e) a single chain antibody fragment.

Metadata:
- Claim Count in Document: 11.0
- Percentile: 97.0
- Lexical Diversity: 1.33803
- Patent Class: 424.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['13094482', '12727912', '13799048', '12239107', '15960070']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7777517450920842
- 35 USC 102 Novelty (BERT): 0.5444985444059166
- Combined Prediction Score: 0.7544264250234675
- Mean Citation Score: 335.76238
- Max Citation Score: 392.83173
- Similarity Product: 381.6567863867855

Labels:
- Claim Label 101: 0
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 0

Dataset: test